Seattle Children’s has launched BrainChild Bio to accelerate cures for kids through the advancement of pediatric chimeric antigen receptor #CARTcell therapies in Central Nervous System (CNS) tumors. bit.ly/4a3QQL9

It’s a great week for kids and their families, and a terrible one for brain tumors. Building upon pioneering research from Seattle Children's Therapeutics (SCTx), Seattle Children's has launched BrainChild Bio to accelerate cures for kids with CNS tumors. fiercebiotech.com/biotech/kid-fi…

The use of CD19t T-APCs (manufactured T cells with a CD19 tag antigen presenting cells) after SCRI-CAR19 in patients treated for relapsed, refractory CD19+ B-cell acute lymphocytic #leukemia was well tolerated and appeared to enhance CAR T-cell persistence, Dr. Colleen Annesley

Colleen E. Annesley, MD, (Seattle Children's Therapeutics (SCTx)) discussed challenges with manufacturing T-APCs, assessing the cell therapy in clinical trials, and improving access to these kinds of therapies. #celltherapy #leusm #leukemia #ASH23 Read more: cgtlive.com/view/annesley-…

2023 was an eventful year at Seattle Children’s Therapeutics. Check out our year in review for a few of our key milestones and recent achievements. 🔬 bit.ly/3TNFt4s

Seattle Children’s continues to be committed to building pathways into pediatric biomedical research through its successful summer internship program for undergraduate students. Submit your application to our Summer Scholars Program by Jan. 12. bit.ly/47KPZxi

Congress is once again racing against the clock to pass a Continuing Resolution and avert a shutdown. As #ChildhoodCancer advocates, we know that robust, predictable, and sustained funding for the NIH and NCI is critical for continued progress in the fight against cancer.

A decline in cancer deaths is promising, yet more work is necessary. This is especially true for children and teens, as cancer remains the 2nd most common cause of death among children and 4th most common cause of death among adolescents in the US. Our work will continue until we

Seattle Children’s neurosurgeons perform significantly more brain tumor operations on children than any other hospital in the region. Learn more: bit.ly/48rw470

We love to show visitors where the magic happens. In our #CureFactory, we specialize in translating laboratory discoveries into real-world treatments.

As one of the largest and most comprehensive pediatric brain tumor programs in the world, Seattle Children’s has specialists to cover every aspect of your child’s care. Learn more: bit.ly/48rw470

Seattle Children’s Brain Tumor Program gives your child access to some of the most advanced treatments and clinical trials of any children’s hospital in the country. 🧡 bit.ly/48rw470

Continuing some great reporting from Isa Cueto and Angus Rohan Chen over the last couple years, I wrote about a small, new study on the big potential for CAR-T therapy in autoimmune disorders: statnews.com/2024/02/21/car…

People with autoimmune disorders don’t usually get to talk about a cure. But a small new study is raising hopes CAR-T therapy could one day change that. trib.al/GN9vmmO

We are proud to announce Seattle Children’s has received U.S. FDA authorization to launch the first chimeric antigen receptor (CAR) T-cell clinical trial in the U.S. for children under 18 with the most common form of lupus. bit.ly/43eFSQ7

Some exciting news from Seattle Children's. Looking forward to working with Seattle Children's Therapeutics (SCTx) to lead the first US clinical trial of anti-CD19 CAR T cells in childhood-onset SLE. Seattle Children's

Children with #lupus face a lifetime of serious health complications. Dr. Shaun Jackson's hope is that one day #CARTcell therapy may help patients with lupus achieve complete remission. bit.ly/48Z0KvK

Read the latest manuscript from Dr. Jacob Applebaum, research fellow and attending physician Fred Hutch Cancer Center, and in collaboration with Seattle Children’s Therapeutics, highlighting drug-regulated CD33-targeted #CARTCells, recently published Journal of Clinical Investigation. bit.ly/4b15u5J